Diabetestherapie: Was hat sich geändert?

Dietlein, Michael

doi:10.1007/s15006-019-0906-9

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diabetic nephropathy is characterized by excessive matrix protein deposition which eventually causes end-stage renal failure (Buse et al, 2020;Davies et al, 2022;Dietlein, 2019). Matrix-triggering mediators that can increase protein deposition include transforming growth factor-β (TGF-β), which has been shown to increase serum transcription and Serine/threonine-threonine-protein kinase (SGK1)-induced glucocorticoid kinases (Zhang et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

Analysis of Urinary Fibronectin Levels in Patients with Type 2 Diabetes Mellitus and Non-Diabetes Mellitus

Kurniawan,

Nurahmi

et al. 2023

fitofarmaka JIF

View full text Add to dashboard Cite

Diabetic nephropathy is a microvascular complication associated with high glucose levels in individuals with diabetes mellitus (DM). Fibronectin, an early marker of diabetic nephropathy, can indicate the occurrence and progression of renal damage. This cross-sectional study aimed to compare urinary fibronectin levels in patients with type 2 diabetes mellitus and non-diabetes mellitus. A sample of 50 DM patients was divided into two groups: the DM group and the non-DM group. Urinary fibronectin levels were measured using the ELISA method, while albuminuria levels were determined by the albumin-to-creatinine ratio (ACR). Statistical analysis was performed to assess the relationship between urinary fibronectin levels and urine albumin. Results: The average urinary fibronectin level in DM patients was 2.07 ± 3.04 ng/mL, which was slightly higher than the level observed in non-DM patients (1.09 ± 0.56 ng/mL). However, this difference was not statistically significant (p 0.05). Additionally, there was no significant relationship found between urinary fibronectin levels and urine albumin (p = 0.001). Conclusion: The findings of this study indicate that urinary fibronectin levels in individuals with DM were slightly higher than those without DM. However, this difference did not reach statistical significance. The lack of a significant relationship between urinary fibronectin levels and urine albumin suggests that fibronectin may provide additional information about renal damage in DM patients, independent of albuminuria. Further research is necessary to explore the clinical significance of urinary fibronectin as a potential biomarker for diabetic nephropathy.

show abstract

Section: Introductionmentioning

confidence: 99%

Analysis of Urinary Fibronectin Levels in Patients with Type 2 Diabetes Mellitus and Non-Diabetes Mellitus

Kurniawan,

Nurahmi

et al. 2023

fitofarmaka JIF

View full text Add to dashboard Cite

show abstract

Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study

Lugner

Sattar

Miftaraj

et al. 2021

Cardiovasc Diabetol

View full text Add to dashboard Cite

Background Major prospective randomized clinical safety trials have demonstrated beneficial effects of treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium–glucose co-transporter-2 inhibitors (SGLT-2i) in people with type 2 diabetes and elevated cardiovascular risk, and recent clinical treatment guidelines therefore promote early use of these classes of pharmacological agents. In this Swedish nationwide observational study, we compared cardiorenal outcomes and safety of new treatment with GLP-1RA and SGLT-2i in people with type 2 diabetes. Methods We linked data from national Swedish databases to capture patient characteristics and outcomes and used propensity-score based matching to account for differences between the two groups. The treatments were compared using Cox regression models. Results We identified 9648 participants starting GLP-1RA and 12,097 starting SGLT-2i with median follow-up times 1.7 and 1.1 years, respectively. The proportion of patients with a history of MACE were 15.8%, and 17.0% in patients treated with GLP-1RA and SGLT-2i, respectively. The mean age was 61 years with 7.6 years duration of diabetes. Mean HbA1c were 8.3% (67.6 mmol/mol) and 8.3% (67.2 mmol/mol), and mean BMI 33.3 and 32.5 kg/m2 in patients treated with GLP-1RA or SGLT-2i, respectively. The cumulative mortality risk was non-significantly lower in the group treated with SGLT-2i, HR 0.78 (95% CI 0.61–1.01), as were incident heart failure outcomes, but the risks of cardiovascular or renal outcomes did not differ. The risks of stroke and peripheral artery disease were higher in the SGLT-2i group relative to GLP-1RA, with HR 1.44 (95% CI 0.99–2.08) and 1.68 (95% CI 1.04–2.72), respectively. Conclusions This observational study suggests that treatment with GLP-1RA and SGLT-2i result in very similar cardiorenal outcomes. In the short term, treatment with GLP-1RA seem to be associated with lower risks of stroke and peripheral artery disease, whereas SGLT-2i seem to be nominally associated with lower risk of heart failure and total mortality.

show abstract

Diabetestherapie: Was hat sich geändert?

Cited by 2 publications

References 0 publications

Analysis of Urinary Fibronectin Levels in Patients with Type 2 Diabetes Mellitus and Non-Diabetes Mellitus

Analysis of Urinary Fibronectin Levels in Patients with Type 2 Diabetes Mellitus and Non-Diabetes Mellitus

Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study

Contact Info

Product

Resources

About